## Safety Data Sheet



#### Section 1: Identification

Product identifier

**Product Name** 

AMYTAL® Sodium CII (Amobarbital Sodium for Injection, USP)

**Product Code**  NDC 0187-4303-05: NDC 42998-303-01 **Product Description** 

· Prescription pharmaceutical product.

Relevant identified uses of the substance or mixture and uses advised against

Recommended use Sedative; hypnotic, for the short-term treatment of insomnia, since it appears to lose

its effectiveness for sleep induction and sleep maintenance after 2 weeks; preanesthetic.

Restrictions on use Refer to the product insert and/or prescribing information for restrictions on use and contraindications.

Details of the supplier of the safety data sheet

Manufacturer Valeant Pharmaceuticals North America, LLC

400 Somerset Corporate Blvd.

Bridgewater, NJ 08807

United States valeant.com

**Telephone (General)** • 1-800-321-4576

**Emergency telephone number** 

Manufacturer • 1-800-535-5053 - US - Infotrac

Manufacturer +1 352-323-3500 - International - Infotrac

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to consumer use of the product.

### Section 2: Hazard Identification

#### **UN GHS**

According to: UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

## Classification of the substance or mixture

**UN GHS** Acute Toxicity Oral 3

Specific Target Organ Toxicity Single Exposure 3: Narcotic Effects

Carcinogenicity 2 Reproductive Toxicity 1

Label elements **UN GHS** 

#### **DANGER**







Hazard statements . Toxic if swallowed

May cause drowsiness or dizziness Suspected of causing cancer.

May damage fertility or the unborn child.

**Precautionary statements** 

**Prevention** • Wash thoroughly after handling.

Do not handle until all safety precautions have been read and understood.

Avoid breathing dust, fume, gas, mist, vapours and/or spray.

Use personal protective equipment as required.

Response • IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

**Storage/Disposal** • Store in a well-ventilated place. Keep container tightly closed.

Dispose of content and/or container in accordance with local, regional, national, and/or

international regulations.

Other hazards

UN GHS
 No data available

## Section 3 - Composition/Information on Ingredients

#### Substances

Composition			
Chemical Name	Identifiers	%	
Amobarbital sodium	CAS:64-43-7	100%	
Amobarbitai soulum	<b>EINECS:</b> 200-584-9	10076	

#### **Mixtures**

Material does not meet the criteria of a mixture.

#### Section 4: First-Aid Measures

## **Description of first aid measures**

Inhalation

 Normal use of this product does not pose an inhalation hazard. However, should respiratory tract irritation develop, discontinue use and remove to fresh air. Get medical attention if irritation or other symptoms develop or persist.

Skin

Wash skin with soap and water. If skin irritation occurs: Get medical advice/attention.
 Wash clothing separately before reuse.

Eye

 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.

Ingestion

 If swallowed, wash out mouth with water provided person is conscious. Seek medical attention.

#### Most important symptoms and effects, both acute and delayed

 Symptoms of oral overdose may occur within 15 minutes beginning with CNS depression, absent or sluggish reflexes, underventilation, hypotension, and hypothermia and may progress to pulmonary edema and death. Hemorrhagic blisters may develop, especially at pressure points.

## Indication of any immediate medical attention and special treatment needed

**Notes to Physician** 

Protect the patient's airway and support ventilation and perfusion. Meticulously

Preparation Date: 08/January/2016 Format: GHS Language: English (US)
Revision Date: 08/January/2016 UN GHS
Page 2 of 8

monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.

### Other information

Have the product container or label with you when calling a poison control center or doctor, or going for treatment. Additional details are availabe on the product package insert or the Physicians Desk Reference.

## Section 5: Fire-Fighting Measures

## Extinguishing media

Suitable Extinguishing Media • SMALL FIRES: Dry chemical, CO2, water spray or regular foam.

LARGE FIRE: Water spray, fog or regular foam.

**Unsuitable Extinguishing** Media

**Firefighting Procedures** 

· No data available

 As in any fire, wear self-contained breathing apparatus and full protective gear to prevent contact with skin and eyes.

## Special hazards arising from the substance or mixture

**Unusual Fire and Explosion** 

Hazards

**Hazardous Combustion** 

**Products** 

Advice for firefighters

• None known - product is not flammable or combustible.

No data available

Structural firefighters' protective clothing provides limited protection in fire situations ONLY; it is not effective in spill situations where direct contact with the substance is possible.

#### Section 6 - Accidental Release Measures

## Personal precautions, protective equipment and emergency procedures

#### **Personal Precautions**

 Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Evacuate immediate area. Ventilate enclosed areas.

#### **Emergency Procedures**

 Keep unauthorized personnel away. For bulk material spills: Contain spilled product. For small spills, add suitable absorbent material. Scoop up and place in an appropriate liquid-tight container equipped with a tight cover for disposal. For large spills, dike spilled material or otherwise contain material to ensure runoff does not reach a waterway. Place spilled material in an appropriate, liquid-tight container equipped with a tight cover for disposal. Ventilate closed spaces before entering.

## **Environmental precautions**

 Prevent spilled material from entering storm sewers or drains, waterways, and contact with soil.

## Methods and material for containment and cleaning up

Containment/Clean-up Measures

 Isolate hazard area. Prevent from entering drains and sewers. Cover with vermiculite or other suitable inert material, pick up and place in closed containers. Transport outdoors and hold for waste disposal. Ventilate area and wash spill site after material pickup is complete. Refer to Section 13 for appropriate disposal procedures.

#### Reference to other sections

Refer to Section 8 - Exposure Controls/Personal Protection and Section 13 - Disposal

Preparation Date: 08/January/2016 Format: GHS Language: English (US) Revision Date: 08/January/2016 **UN GHS** Page 3 of 8

#### Considerations.

## Section 7 - Handling and Storage

### Precautions for safe handling

#### Handling

Use only in well ventilated areas (preferably in a chemical fume hood). Do not breathe
dusts, vapors or mists. Do not get in eyes, on skin, or on clothing. Avoid prolonged or
repeated exposure. Wash thoroughly after handling. Use good safety and industrial
hygiene practices.

## Conditions for safe storage, including any incompatibilities

Storage

• Keep tightly closed. Store at room temperature 15-30°C (59-86°F), to maintain product integrity, use before expiration date marked on carton and/or container.

## **Section 8 - Exposure Controls/Personal Protection**

## **Control parameters**

**Exposure Limits/Guidelines** 

 Refer to the occupational exposure limits / guidelines for the individual product components.

## **Exposure controls**

Engineering Measures/Controls  Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

## **Personal Protective Equipment**

**Pictograms** 







#### Respiratory

• Where risk assessment shows that air-purifying respirators are appropriate, a NIOSH (US) or CEN (EU) -certified air-purifying respirator equipped with HEPA and organic vapor cartridges may be permissible under certain circumstances where airborne concentrations are expected to exceed exposure limits, when adequate oxygen is present and as a backup to engineering controls. Use a positive pressure air-supplied respirator if there is any potential for an uncontrolled release or any other circumstances where air purifying respirators may not provide adequate protection.

Eye/Face

Wear protective eyewear (goggles, face shield, or safety glasses) when handling bulk product before closed in final packaging. Not required during normal clinical use.

Hands

Wear protective gloves.

Skin/Body

 Wear protective gloves/protective clothing/eye protection/face protection. Not required during normal clinical use.

General Industrial Hygiene Considerations

 Handle in accordance with good industrial hygiene and safety practice. Do not eat, drink or smoke during work. Avoid contact with skin, eyes or clothing. Wash thoroughly after handling.

**Environmental Exposure Controls** 

 No special controls are required under conditions of intended use. In the event of a bulk spill, prevent spilled material from entering storm sewers or drains, waterways, and contact with the soil.

## **Section 9 - Physical and Chemical Properties**

## **Information on Physical and Chemical Properties**

Material Description				
Physical Form	Solid	Appearance/Description	white, friable, lyophilized granular powder.	
Color	White	Odor	No odor.	
General Properties		-	-	
Boiling Point	No data available	Melting Point/Freezing Point	No data available	
Decomposition Temperature	No data available	рН	No data available	
Specific Gravity/Relative Density	No data available	Water Solubility	Not relevant	
Viscosity	Not relevant			
Volatility				
Vapor Pressure	Not relevant	Vapor Density	Not relevant	
Evaporation Rate	Not relevant			
Flammability				
Flash Point	Not relevant	UEL	Not relevant	
LEL	Not relevant	Autoignition	Not relevant	
Flammability (solid, gas)	Not relevant			
Environmental				
Octanol/Water Partition coefficient	No data available			

## **Section 10: Stability and Reactivity**

## Reactivity

· No dangerous reaction known under conditions of normal use.

## **Chemical stability**

Stable under normal temperatures and humidities.

## Possibility of hazardous reactions

· No data available

## **Conditions to avoid**

• Extreme heat or cold. Do not freeze.

## Incompatible materials

• This product is generally compatible with other common materials in a medical facility.

## **Hazardous decomposition products**

· No data available

## **Section 11 - Toxicological Information**

## Information on toxicological effects

Components			
Amobarbital sodium (100%)	64-43-7	Acute Toxicity: Ingestion/Oral-Mouse LD50 • 505 mg/kg; Ingestion/Oral-Rat LD50 • 275 mg/kg	

GHS Properties	Classification	
Acute toxicity	UN GHS • Acute Toxicity - Oral 3	
Skin corrosion/Irritation UN GHS • Classification criteria not met		
Serious eye damage/Irritation	UN GHS • Classification criteria not met	

Preparation Date: 08/January/2016 Revision Date: 08/January/2016 Format: GHS Language: English (US)
UN GHS

Skin sensitization	UN GHS • Classification criteria not met	
Respiratory sensitization	UN GHS • Classification criteria not met	
Aspiration Hazard	UN GHS • Classification criteria not met	
Carcinogenicity	UN GHS • Carcinogenicity 2	
Germ Cell Mutagenicity	UN GHS • Classification criteria not met	
Toxicity for Reproduction	UN GHS • Toxic to Reproduction 1	
STOT-SE	UN GHS • Specific Target Organ Toxicity Single Exposure 3: Narcotic Effects	
STOT-RE	UN GHS • Classification criteria not met	

#### **Target Organs**

Central nervous system

# Potential Health Effects Inhalation

Acute (Immediate)

• Under normal conditions of use, no health effects are expected.

Chronic (Delayed)

No data available

Skin

Acute (Immediate)
Chronic (Delayed)

• Non-irritating to skin or mucous membranes when used as directed.

No data available

Eye

Acute (Immediate)

May cause mild eye irritation with direct contact to eye.

**Chronic (Delayed)** 

· No data available

Ingestion

Acute (Immediate)

 Not expected to be an exposure route. However, may cause gastric and intestinal irritation if ingested.

Chronic (Delayed)

· No data available

Carcinogenic Effects

• Animal Data. Phenobarbital sodium is carcinogenic in mice and rats after lifetime adminis- tration. In mice, it produced benign and malignant liver cell tumors. In rats, benign liver cell tumors were observed very late in life. Human Data — In a 29-year epidemiologic study of 9,136 patients who were treated on an anticonvulsant protocol that included phenobarbital, results indicated a higher than normal incidence of hepatic carcinoma. Previously, some of these patients had been treated with thorotrast, a drug that is known to produce hepatic carcinomas. Thus, this study did not provide sufficient evidence that phenobarbital sodium is carcinogenic in humans. A retrospective study of 84 children with brain tumors matched to 73 normal controls and 78 cancer controls (malignant disease other than brain tumors) suggested an association between exposure to barbiturates prenatally and an increased incidence of brain tumors.

#### **Reproductive Effects**

Barbiturates can cause fetal damage when administered to a pregnant woman.
Retrospective, case-controlled studies have suggested a connection between the
maternal consumption of barbiturates and a higher than expected incidence of fetal
abnormalities. Barbiturates readily cross the placental barrier and are distributed
throughout fetal tissues; the highest concentrations are found in the placenta, fetal
liver, and brain. Fetal blood levels approach maternal blood levels following parenteral
administration. Withdrawal symptoms occur in infants born to women who receive
barbiturates throughout the last trimester of pregnancy.

## **Section 12 - Ecological Information**

## **Toxicity**

This material has not been tested for environmental effects.

## Persistence and degradability

No data available

## Bioaccumulative potential

No data available

## **Mobility in Soil**

No data available

#### Other adverse effects

## **Section 13 - Disposal Considerations**

### Waste treatment methods

**Product waste** Waste characterizations and compliance with applicable laws are the responsibility

solely of the waste generator.

Packaging waste · Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

## **Section 14 - Transport Information**

	UN number	UN proper shipping name	Transport hazard class (es)	Packing group	Environmental hazards
DOT	Not Applicable	Not Regulated	Not Applicable	Not Applicable	
IMO/IMDG	Not Applicable	Not Regulated	Not Applicable	Not Applicable	
IATA/ICAO	Not Applicable	Not Regulated	Not Applicable	Not Applicable	

Special precautions for user • No data available

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

No data available

## **Section 15 - Regulatory Information**

## Safety, health and environmental regulations/legislation specific for the substance or mixture SARA Hazard Classifications • No data available

Inventory				
Component	CAS	Canada DSL	EU EINECS	TSCA
Amobarbital sodium	64-43-7	Yes	Yes	No

### **United States - California**

Environment U.S California - Proposition 65 - Carcinogens List  • Amobarbital sodium	64-43-7	Not Listed
U.S California - Proposition 65 - Developmental Toxicity  • Amobarbital sodium	64-43-7	Not Listed
U.S California - Proposition 65 - Reproductive Toxicity - Female  • Amobarbital sodium	64-43-7	Not Listed

Preparation Date: 08/January/2016 Revision Date: 08/January/2016

Format: GHS Language: English (US) **UN GHS** 

U.S. - California - Proposition 65 - Reproductive Toxicity - Male

Amobarbital sodium
 64-43-7
 Not Listed

## **Section 16 - Other Information**

Revision Date
Last Revision Date
Preparation Date
Disclaimer/Statement of
Liability

- 08/January/2016
- 08/January/2016
- 08/January/2016
- The above information and recommendations contained in the Safety Data Sheet have been compiled from sources believed to be accurate and reliable and to represent the most reasonable current opinion on the subject as of the date the SDS was prepared. No warranty, guaranty, or representation is made as to the correctness or sufficiency of the information. Such data are offered solely for consideration, investigation, and verification but do not purport to be all inclusive and should be used only as a guide. The user of this product must decide what safety measures are necessary to safely use this product, either alone or in combination with other products, and determine its environmental regulatory compliance obligations under any applicable federal or state laws.